References
- Letsas KP, Filippatos GS, Kounas SP, et al. QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone. Cardiology. 2006;105(3):146–147.
- Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med.. 2004;350(10):1013–1022.
- Jehle J, Ficker E, Wan X, et al. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol. 2013;168(5):1215–1229.
- von Moltke LL, Weemhoff JL, Perloff MD, et al. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002;23(9):361–367.
- Hesse LM, Venkatakrishnan K, Moltke LL. V, et al. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001;29(2):133–140.